Holen Sie sich die Stockscreener-App
29.37
6.42%
-2.02
Schlusskurs vom Vortag:
$31.39
Offen:
$31.16
24-Stunden-Volumen:
576.36K
Relative Volume:
0.42
Marktkapitalisierung:
$1.32B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-47.20M
KGV:
-18.76
EPS:
-1.5653
Netto-Cashflow:
$-43.65M
1W Leistung:
-11.41%
1M Leistung:
+14.88%
6M Leistung:
+158.59%
1J Leistung:
+28.67%
1-Tages-Spanne:
$29.28
$31.96
1-Wochen-Bereich:
$28.01
$34.60
52-Wochen-Spanne:
$4.8069
$34.83
Mbx Biosciences Inc Stock (MBX) Company Profile
Firmenname
Mbx Biosciences Inc
Sektor
Branche
Telefon
(317) 989-3100
Adresse
11711 N. MERIDIAN STREET, CARMEL
Vergleichen Sie MBX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
29.30 | 1.41B | 0 | -47.20M | -43.65M | -1.5653 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.97 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.88 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
892.65 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.75 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-04 | Eingeleitet | Goldman | Sell |
| 2025-11-04 | Eingeleitet | TD Cowen | Buy |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-08-15 | Fortgesetzt | Jefferies | Buy |
| 2025-08-05 | Eingeleitet | Mizuho | Outperform |
| 2025-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-10 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | JP Morgan | Overweight |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Stifel | Buy |
Alle ansehen
Mbx Biosciences Inc Aktie (MBX) Neueste Nachrichten
Certain Common Stock of MBX Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 9-DEC-2025. - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), MBX Biosciences, Inc. (MBX) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Goldman Sachs initiates coverage of MBX Biosciences (MBX) with sell recommendation - MSN
Goldman Sachs Initiates Coverage of MBX Biosciences (MBX) with Sell Recommendation - Nasdaq
MBX Biosciences (MBX) Is Down 9.7% After Goldman Sell Call and MPM ExitWhat's Changed - Yahoo Finance
Goldman Sachs initiates MBX Biosciences stock with Sell rating on platform concerns - Investing.com Nigeria
Goldman Sachs initiates MBX Biosciences stock with Sell rating on platform concerns By Investing.com - Investing.com South Africa
MBX Biosciences drops 4% in premarket trading after Goldman initiates with sell - MSN
MBX Biosciences initiated with a sell at Goldman Sachs - MSN
Goldman Sachs Initiates Coverage on MBX with Sell Rating | MBX S - GuruFocus
Goldman Sachs Initiates Coverage on MBX Biosciences With Sell Rating, $18 Price Target - marketscreener.com
MBX Biosciences initiated with a Sell at Goldman Sachs - TipRanks
Is MBX Biosciences Inc. stock attractive for growth ETFsJuly 2025 News Drivers & Technical Analysis for Trade Confirmation - Newser
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones - Yahoo Finance
Sio Capital Management LLC Acquires New Holdings in MBX Biosciences, Inc. $MBX - MarketBeat
How MBX Biosciences Inc. stock benefits from global expansionGold Moves & Growth Focused Stock Pick Reports - Newser
MBX Biosciences (MBX) Stock Analysis Report | Financials & Insights - Benzinga
MBX Biosciences (NASDAQ:MBX) Sets New 12-Month HighHere's What Happened - MarketBeat
Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus - MSN
How Much Upside is Left in MBX Biosciences, Inc. (MBX)? Wall Street Analysts Think 80.6% - MSN
MBX Biosciences, Inc. $MBX Shares Purchased by Franklin Resources Inc. - MarketBeat
Rockefeller Capital Management L.P. Acquires Shares of 34,135 MBX Biosciences, Inc. $MBX - MarketBeat
MBX Biosciences (NASDAQ:MBX) Trading Up 5.6%Should You Buy? - MarketBeat
MBX S-8 & SEC Filings - Yahoo Finance Australia
MBX Biosciences Advances Phase 2a Study on PBH Treatment with Imapextide - MSN
Mbx biosciences stock reaches all-time high at 32.16 USD - Investing.com
Mbx biosciences stock reaches all-time high at 32.16 USD By Investing.com - Investing.com Australia
MBX: Once-monthly obesity candidate MBX 4291 shows strong potential for best-in-class tolerability and efficacy - TradingView
Will MBX Biosciences Inc. stock outperform tech sector in 2025Earnings Miss & Low Risk High Reward Ideas - newser.com
Is MBX Biosciences Inc. stock a safe buy before earningsSell Signal & Precise Swing Trade Entry Alerts - newser.com
Will MBX Biosciences Inc. stock rally after Fed decisionsTrade Risk Report & AI Enhanced Trade Execution Alerts - newser.com
MBX Biosciences, Inc. (NASDAQ:MBX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
MBX Biosciences stock maintains Buy rating at Jefferies on strong Phase 2 data By Investing.com - Investing.com South Africa
MBX Biosciences stock maintains Buy rating at Jefferies on strong Phase 2 data - Investing.com Nigeria
Can MBX Biosciences Inc. stock resist sector downturns - newser.com
Will MBX Biosciences Inc. stock remain a Wall Street favorite2025 Technical Patterns & Risk Controlled Daily Trade Plans - newser.com
MBX: Strong clinical progress and funding position drive multiple catalysts in endocrine and metabolic pipeline - TradingView
MBX: Strong clinical progress and funding drive late-stage catalysts in endocrine and metabolic programs - TradingView
How rising interest rates impact MBX Biosciences Inc. stockQuarterly Performance Summary & Precise Entry and Exit Recommendations - newser.com
Chart based exit strategy for MBX Biosciences Inc.Recession Risk & Smart Swing Trading Techniques - newser.com
Visualizing MBX Biosciences Inc. stock with heatmapsQuarterly Growth Report & Consistent Profit Trading Strategies - newser.com
Finanzdaten der Mbx Biosciences Inc-Aktie (MBX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):